First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas is a paper indexed in PICO Portal from OpenAlex.
How many citations does First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas have?
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas has 767 citations in the OpenAlex counts PICO Portal stores.
When was First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas published?
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas has 2010 year in the PICO Portal index.
What is the open-access status of First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas?
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas has bronze oa status in the PICO Portal index.
What is the DOI of First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas?
The DOI for First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas is on the source record.
What is the PMID of First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas?
The PMID for First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas is on the source record.
What is the OpenAlex record for First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas?
The OpenAlex for First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas is on the source record.